Hormone replacement therapy after treatment for a gynaecological malignancy

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 1, 2016, Pages 32-41

  O'Donnell, Rachel Louise ^a   Clement, Katherine M ^b   Edmondson, Richard J ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b New Croft Centre   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Hormone receptor; Hormone replacement therapy; Malignancy; Menopause; Recurrence

Indexed keywords

ADULT; AGED; COMPLICATION; DRUG EFFECTS; EARLY MENOPAUSE; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH CARE DELIVERY; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINE; PROCEDURES; QUALITY OF LIFE; SURVIVOR; TUMOR RECURRENCE;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH SERVICES ACCESSIBILITY; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE, PREMATURE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; SURVIVORS;

EID: 84952977509     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000238     Document Type: Review

References (99)

1. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010; 65:190-197.
2. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review. Climacteric 2001; 4:58-74.
3. de Kleijn MJ, van der Schouw YT, Verbeek AL, et al. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002; 155:339-345.
4. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061-1066.
5. Studd JW, Holland EF, Leather AT, Smith RN. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994; 101:787-791.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
7. Panay N, Hamoda H, Arya R, et al. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int 2013; 19:59-68.
8. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; CD001500.
9. Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal 2007; 5:e003.
10. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76:636-652.
11. Lu NZ, Wardell SE, Burnstein KL, et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006; 58:782-797.
12. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304:1269- 1273.
13. Hapgood JP, Koubovec D, Louw A, Africander D. Not all progestins are the same: implications for usage. Trends Pharmacol Sci 2004; 25:554-557.
14. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays Biochem 2004; 40:105-120.
15. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010; 82:410-417.
16. Kim JK, Levin ER. Estrogen signaling in the cardiovascular system. Nucl Recept Signal 2006; 4:e013.
17. Tastan I, Schreckenberg R, Mufti S, et al. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a nonacute way. Cardiovasc Res 2009; 82:77-83.
18. Iqbal J, Sun L, Kumar TR, et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006; 103:14925-14930.
19. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006; 125:247-260.
20. Iqbal J, Zaidi M. Understanding estrogen action during menopause. Endocrinology 2009; 150:3443-3445.
21. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Ann Rev Physiol 2005; 67:335-376.
22. Sonnet E, Lacut K, Roudaut N, et al. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol 2007; 66:626-631.
23. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemos 1992; 68:392-395.
24. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial. Arterioscler Thromb Vasc Biol 2003; 23:1671-1676.
25. Lawson JS, Field AS, Tran DD, Houssami N. Hormone replacement therapy use dramatically increases breast oestrogen receptor expression in obese postmenopausal women. Breast Cancer Res 2001; 3:342-345.
26. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366:491-505.
27. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64:417-420.
28. Whitaker GK, Lee RB, Benson WL. Carcinoma of the endometrium in young women. Mil Med 1986; 151:25-31.
29. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67:326-330.
30. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36:189-191.
31. Baker DP. Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990; 16:28-35.
32. Bryant GW. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990; 83:725-726.
33. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175:1195-1200.
34. Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: A matched control study. Obstet Gynecol 2001; 97:555-560.
35. Shim S-H, Lee SJ, Kim S-N. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: A meta-analysis. Eur J Cancer 2014; 50:1628-1637.
36. Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int J Cancer 2010; 127:1692-1698.
37. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543-1551.
38. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2006; 24:587- 592.
39. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369:1703-1710.
40. Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010; 16:89-93.
41. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006; 16:805-808.
42. Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69:220-225.
43. Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990; 38:59-65.
44. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 2001; 438:470- 477.
45. Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995; 59:347-351.
46. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007; 43:2434- 2444.
47. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003; 23:729- 732.
48. Guntupalli SR, Cao D, Shroff R, et al. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma. Ann Surg Oncol 2013; 20:2373-2379.
49. Yue X, Utsunomiya H, Akahira JI, et al. Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma. Oncol Lett 2013; 5:835-839.
50. Biliatis I, Thomakos N, Rodolakis A, et al. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol 2012; 32:321-325.
51. Dunton CJ, Kelsten ML, Brooks SE, et al. Low-grade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data. Gynecol Oncol 1990; 37:268-275.
52. Buekers TE, Anderson B, Sorosky JI, Buller RE. Ovarian function after surgical treatment for cervical cancer. Gynecol Oncol 2001; 80:85-88.
53. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987; 26:169-177.
54. Lacey JV Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000; 77:149-154.
55. Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol 2010; 73:707-714.
56. Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009; 53:805-811.
57. O'Donnell RL, Warner P, Lee RJ, et al. Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. Hum Reprod 2012; 27:1130-1138.
58. Critchley HO, Buckley CH, Anderson DC. Experience with a 'physiological' steroid replacement regimen for the establishment of a receptive endometrium in women with premature ovarian failure. Br J Obstet Gynaecol 1990; 97:804-810.
59. Winarto H, Febia E, Purwoto G, Nuranna L. The need for laparoscopic ovarian transposition in young patients with cervical cancer undergoing radiotherapy. Int J Reprod Med 2013; 2013:173-568.
60. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy- long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67:327-332.
61. Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302:259-262.
62. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999; 86:1013-1018.
63. Bebar S, Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur J Gynaecol Oncol 2000; 21:192-196.
64. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001; 8:70-75.
65. Mascarenhas C, Lambe M, Bellocco R, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006; 119:2907-2915.
66. E W. Estrogen, Progestin substitution therapy following treatment for ovarian cancer. Proceedings of the Eleventh International Menopause Congress Bangkok. 1991.
67. McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology 2011; 43:420-432.
68. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2010; 3:CD001034.
69. Sjoquist KM, Martyn J, Edmondson RJ, Friedlander ML. The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer 2011; 21:1328-1333.
70. Scambia G, Ferrandina G, D'Agostino G, et al. Oestrogen and progesterone receptors in ovarian carcinoma. Endocrine Relat Cancer 1998; 5:293-301.
71. Ward HW. Progestogen therapy for ovarian carcinoma. J Obstet Gynaecol Br Commonw 1972; 79:555-559.
72. Myers AM, Moore GE, Major FJ. Advanced ovarian carcinoma: response to antiestrogen therapy. Cancer 1981; 48:2368-2370.
73. Schwartz PE, Keating G, MacLusky N, et al. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982; 59:583-588.
74. Geisler HE. Megestrol acetate for the palliation of advanced ovarian carcinoma. Obstet Gynecol 1983; 61:95-98.
75. Weiner SA, Alberts DS, Surwit EA, et al. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987; 27:208-213.
76. Kobayashi H, Sumimoto K, Moniwa N, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: A cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007; 17:37-43.
77. Brinton LA, Sakoda LC, Sherman ME, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol 2005; 14:2929-2935.
78. Rossing MA, Cushing-Haugen KL, Wicklund KG, et al. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Cause Control 2008; 19:1357-1364.
79. Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006; 9:325-335.
80. Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005; 97:780-783.
81. Zalel Y, Piura B, Elchalal U, et al. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet 1996; 55:1-10.
82. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003; 101:251-257.
83. Wren B. Hormonal therapy and genital tract cancer. Curr Opin Obstet Gynecol 1996; 8:38-41.
84. Miller JG, Gee J, Price A, et al. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res 1997; 7:197-208.
85. Cohen C, DeRose PB, Campbell WG, et al. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 1990; 12:562-564.
86. Durvasula R, Ahmed SM, Vashisht A, Studd JW. Hormone replacement therapy and malignant melanoma: to prescribe or not to prescribe? Climacteric 2002; 5:197-200.
87. Kreuser ED, Felsenberg D, Behles C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients followingCOPP/ABVDchemotherapy for Hodgkin's disease. Ann Oncol 1992; 3 (Suppl 4):105-110.
88. Howell SJ, Berger G, Adams JE, Shalet SM. Bone mineral density in women with cytotoxic-induced ovarian failure. Clin Endocrinol 1998; 49:397-402.
89. Ratcliffe MA, Lanham SA, Reid DM, Dawson AA. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol 1992; 10:181-187.
90. Headley JA, Theriault RL, LeBlanc AD, et al. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998; 16:6-11.
91. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005; 16:372-379.
92. Holloway D. An overview of the menopause: Assessment and management. Nurs Stand 2011; 25:47-57.
93. Royal College of Obstetricians and Gynaecologists. Alternatives to HRT for the Management of Symptoms of the Menopause. Scientific Impact Paper No 6. 2010.
94. Ladd CO, Newport DJ, Ragan KA, et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005; 22:94-97.
95. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2003; 101:337-345.
96. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 2005; 366:818-824.
97. Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: A randomized controlled trial. Menopause 2008; 15:310-318.
98. Lindsay R, Hart DM. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978; 1:21-25.
99. Ayers B, SmithM, Hellier J, et al. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): A randomized controlled trial. Menopause 2012; 19:749-759.